Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Abstract NTRK gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods to identify eligible patients. We per...

Descripció completa

Dades bibliogràfiques
Autors principals:	Sophie O’Haire, Fanny Franchini, Yoon-Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox, Maarten IJzerman
Format:	Article
Idioma:	English
Publicat:	Nature Portfolio 2023-03-01
Col·lecció:	Scientific Reports
Accés en línia:	https://doi.org/10.1038/s41598-023-31055-3

Ítems similars

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
per: Yoon-Jung Kang, et al.
Publicat: (2022-11-01)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
per: Simon Strohmeier, et al.
Publicat: (2021-05-01)

NTRK fusion in Japanese colorectal adenocarcinomas
per: Yuya Yamashiro, et al.
Publicat: (2021-03-01)

NTRK1 fusion in glioblastoma multiforme.
per: Jinkuk Kim, et al.
Publicat: (2014-01-01)

<i>NTRK</i> Fusions in 1113 Solid Tumors in a Single Institution
per: Heejin Bang, et al.
Publicat: (2022-06-01)

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
per: Jeongwan Kang, et al.
Publicat: (2020-09-01)

Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors
per: Mariana Petaccia de Macedo, et al.
Publicat: (2023-09-01)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
Publicat: (2014-01-01)

NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas
per: Zoltán Lippai, et al.
Publicat: (2025-01-01)

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
per: Rafal Dziadziuszko, et al.
Publicat: (2022-05-01)

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
per: Chunwei Xu, et al.
Publicat: (2022-11-01)

Case report: Adult NTRK-rearranged spindle cell neoplasms with TPM3-NTRK1 fusion in the pelvic
per: Qiurui Cao, et al.
Publicat: (2024-01-01)

Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
per: Fanny Franchini, et al.
Publicat: (2023-10-01)

NTRK fusions in osteosarcoma are rare and non‐functional events
per: Baptiste Ameline, et al.
Publicat: (2020-04-01)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
per: Matthew Torre, et al.
Publicat: (2020-07-01)

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
per: C. B. Westphalen, et al.
Publicat: (2021-07-01)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma
per: Qing-Xiang Yu, et al.
Publicat: (2023-04-01)

NTRK-rearranged spindle cell tumor with SPECC1L-NTRK3 fusion in the thoracic spine: a case report
per: Mi Zhou, et al.
Publicat: (2024-12-01)

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers
per: Emel Ünal, et al.
Publicat: (2022-11-01)

Dermoscopic Features of Spitz Tumor With LMNA-NTRK1 Fusion
per: Ben J. Friedman, et al.
Publicat: (2020-12-01)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
per: Ruiying Zhao, et al.
Publicat: (2021-07-01)

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
per: Eric Eunshik Kim, et al.
Publicat: (2024-07-01)

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
per: C. B. Westphalen, et al.
Publicat: (2021-09-01)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
per: Yinghuan Dai, et al.
Publicat: (2022-06-01)

Critical domains for NACC2-NTRK2 fusion protein activation.
per: Wei Yang, et al.
Publicat: (2024-01-01)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
per: Vasiliki Siozopoulou, et al.
Publicat: (2022-05-01)

<i>NTRK</i> Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
per: Vasiliki Siozopoulou, et al.
Publicat: (2021-03-01)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
per: Yuekun Wang, et al.
Publicat: (2020-11-01)

Case report: STRN3-NTRK3 fusion in uterine sarcoma with spleen metastasis: a new variant in the spectrum of NTRK-rearranged tumors
per: Piergiuseppe Colombo, et al.
Publicat: (2024-11-01)

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan
per: Eiji Nakata, et al.
Publicat: (2024-06-01)

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets
per: Zhaohui Liao Arter, et al.
Publicat: (2025-02-01)

A case of thyroid carcinoma with mucinous features harboring ETV6-NTRK3 fusion: Expanding the morphologic spectrum of NTRK-rearranged thyroid carcinoma
per: Khaled A. Murshed, et al.
Publicat: (2022-06-01)

Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
per: Bart Koopman, et al.
Publicat: (2022-03-01)

Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland
per: Holger Moch, et al.
Publicat: (2021-03-01)

BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors
per: Jin Sheng, et al.
Publicat: (2024-09-01)

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
per: Markus Eszlinger, et al.
Publicat: (2023-01-01)

Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma
per: Li Lei, et al.
Publicat: (2020-08-01)

Use of Diagnostic Algorithms for NTRK Fusion-Positive Tumors in Pathology Institutes in Switzerland
per: Holger Moch, et al.
Publicat: (2021-03-01)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
per: Salvatore Siena, et al.
Publicat: (2020-10-01)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
per: Monika Durzyńska, et al.
Publicat: (2023-08-01)